title: Uterine size in women with Turner syndrome after induction of puberty with estrogens and long-term growth hormone therapy: results of the German IGLU Follow-up Study 2001.
abstract: BACKGROUND
  To evaluate the factors influencing uterine size in young adult women with Turner syndrome (TS) after long-term growth hormone (GH) treatment.
  
  
  METHODS
  Cross-sectional study. Out of 188 women with TS from 96 German centres, whose longitudinal growth was documented within KIGS (Pfizer International Growth Database), data on uterine size were collected voluntarily at a standardized follow-up visit: 75 TS women (ages: 15.8-30.8 years) with complete data were included. Classification according to karyotype: 45,X (78.6%), 45,X/46,XX (5.4%), 45,X/46,iXq (8%), 45,X/46,XY (8%). Puberty was induced with estrogens in all women. At follow-up, 66 were on cyclic estrogens and progestins.
  
  
  RESULTS
  13/66 (19.6%) TS women who received estrogens had a reduced uterine length <5 cm. Calculating the data in standard deviation scores (SDS), only women with 45,X/46,XX karyotype had normal median uterine length and volume of 0.6 and 1.59 SDS respectively. An incomplete breast development (Tanner stage B 3) was found in women with 45,X karyotype (n = 11; 18.6%) and with 45,X/46,XY (n = 2).
  
  
  CONCLUSIONS
  Only TS women with karyotype 45,X/46,XX had normal uterine sizes, whereas 26% of the TS women with karyotype 45,X had a uterine length <-2 SDS, and 18% a volume <-2 SDS.
authors.affiliation: University Hospital for Children and Adolescents, Erlangen, Germany. hgdoerr@kinder.imed.uni-erlangen.de
authors.forename: Helmuth G
authors.initials: HG
authors.lastname: Doerr
authors.forename: Markus
authors.initials: M
authors.lastname: Bettendorf
authors.forename: Berthold P
authors.initials: BP
authors.lastname: Hauffa
authors.forename: Otto
authors.initials: O
authors.lastname: Mehls
authors.forename: Carl-Joachim
authors.initials: CJ
authors.lastname: Partsch
authors.forename: Elfriede
authors.initials: E
authors.lastname: Said
authors.forename: Sabine
authors.initials: S
authors.lastname: Sander
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Schwarz
authors.forename: Nikolaus
authors.initials: N
authors.lastname: Stahnke
authors.forename: Heiner
authors.initials: H
authors.lastname: Steinkamp
authors.forename: Michael B
authors.initials: MB
authors.lastname: Ranke
mesh_terms: D000293:Adolescent; D000328:Adult; D003430:Cross-Sectional Studies; D005260:Female; D005500:Follow-Up Studies; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007621:Karyotyping; D009929:Organ Size / Q000187:drug effects; D011627:Puberty / Q000187:drug effects*; D012016:Reference Values; D014424:Turner Syndrome / Q000188:drug therapy* / Q000235:genetics; D014463:Ultrasonography; D014599:Uterus / Q000000981:diagnostic imaging / Q000187:drug effects / Q000254:growth & development*
chemical_list: D019382:Human Growth Hormone